On November 13, Kodiak Sciences Inc. fell 4.15% in Regular Trading, trading at $103.74 per share, with turnover of $3.3317 million.
The move followed the company’s quarterly results, with the market focusing on a wider net loss, higher research and development spending, and earnings that came in slightly below expectations.
Kodiak Sciences Inc. reported third-quarter EPS of $1.05 loss, versus an expected $1.01 loss in one market update, while quarterly net loss widened 8% year over year to $66.22 million. Research and development expense rose 16% to $58.3 million, driven by increased clinical and manufacturing activities. The company said its multi-indication biologics license application for Zenkuda remains planned for the fourth quarter, and a separate analyst note later raised the price target to $150 from $120, but the immediate trading reaction appeared centered on the quarter’s loss and cost pressure.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments